Actively Recruiting
Identify Genes/Pathways Responsible for Progression From Low Risk to Higher Risk Prostate Cancer
Led by National Taiwan University Hospital · Updated on 2022-08-12
300
Participants Needed
1
Research Sites
604 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In Taiwan, about 70% of new incident prostate cancer patients have localized disease. Most patients were detected by PSA screening. Among them, many had low-risk PC, which is very likely latent in nature, progresses slowly, and rarely leads to death. Most patients died of other causes, such as other cancers, cardiovascular diseases, and diabetes mellitus. Many guidelines recommend that active surveillance (AS) or watchful waiting (WW) is a good option for low risk patients to avoid overtreatment-related complications. However, 30% of patients on AS will finally need definitive treatments due to disease progression within 10 years. We hypothesize that there are differential gene expressions between progressive and non-progressive tumors. If we can identify key genes or pathways that are responsible for progression of low risk PC to higher risk diseases, PC progression could be reduced substantially by regulating these genes or pathways and maintain long-term cancer latency to control non-metastatic PC. In light of the high prevalence rate of latent PC in adult men, the strategy is in fact the best strategy for preventing clinical PC.
CONDITIONS
Official Title
Identify Genes/Pathways Responsible for Progression From Low Risk to Higher Risk Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or cytologically confirmed adenocarcinoma of the prostate
- Have received or are receiving active surveillance as the main conservative management at National Taiwan University Hospital
- Have had or will have a prostate biopsy to confirm tumor progression after prostate cancer diagnosis
You will not qualify if you...
- Received systemic chemotherapy, pelvic radiotherapy, or androgen deprivation therapy before prostate operation or biopsy specimen collection
- Do not agree to sign the informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Taiwan University
Taipei, Taiwan, 10002
Actively Recruiting
Research Team
Y
Yeong-Shiau Pu, PhD
CONTACT
C
Chung-Hsin Chen, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here